Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Hanauer

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
Inflammatory Bowel Diseases|July 11, 2009
Don't miss the forest for the treesStephen Hanauer
Immunotherapy|December 13, 2022
Plain language summary of the VOLTAIRE-CD study in people with moderate-to-severe active Crohn's diseaseStephen Hanauer
Expert Review of Gastroenterology & Hepatology|April 11, 2022
A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitisRoni Aoun, Stephen Hanauer
The American Journal of Gastroenterology|January 11, 2020
Checkpoint Inhibitor-Induced ColitisEmanuelle Bellaguarda, Stephen Hanauer
Current Treatment Options in Gastroenterology|February 7, 2017
Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel DiseaseShannon Chang, Stephen Hanauer
Expert Review of Clinical Pharmacology|May 6, 2017
Optimizing pharmacologic management of inflammatory bowel diseaseShannon Chang, Stephen Hanauer
Expert Review of Gastroenterology & Hepatology|June 3, 2009
Selecting appropriate anti-TNF agents in inflammatory bowel diseaseLaura Yun, Stephen Hanauer
The Cochrane Database of Systematic Reviews|December 15, 2010
Aminosalicylates for induction of remission or response in Crohn's diseaseWee-Chian Lim, Stephen Hanauer
Alimentary Pharmacology & Therapeutics|October 20, 2021
Review article: drug-induced small bowel injuryShadi Hamdeh, Dejan Micic, Stephen Hanauer
Expert Review of Clinical Immunology|May 25, 2023
The evolving role of JAK inhibitors in the treatment of inflammatory bowel diseaseNancy Gupta, Sam Papasotiriou, Stephen Hanauer
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Inflammatory Bowel Diseases|July 11, 2009
Don't miss the forest for the treesStephen Hanauer
Immunotherapy|December 13, 2022
Plain language summary of the VOLTAIRE-CD study in people with moderate-to-severe active Crohn's diseaseStephen Hanauer
Expert Review of Gastroenterology & Hepatology|April 11, 2022
A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitisRoni Aoun, Stephen Hanauer
The American Journal of Gastroenterology|January 11, 2020
Checkpoint Inhibitor-Induced ColitisEmanuelle Bellaguarda, Stephen Hanauer
Current Treatment Options in Gastroenterology|February 7, 2017
Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel DiseaseShannon Chang, Stephen Hanauer
Expert Review of Clinical Pharmacology|May 6, 2017
Optimizing pharmacologic management of inflammatory bowel diseaseShannon Chang, Stephen Hanauer
Expert Review of Gastroenterology & Hepatology|June 3, 2009
Selecting appropriate anti-TNF agents in inflammatory bowel diseaseLaura Yun, Stephen Hanauer
The Cochrane Database of Systematic Reviews|December 15, 2010
Aminosalicylates for induction of remission or response in Crohn's diseaseWee-Chian Lim, Stephen Hanauer
Alimentary Pharmacology & Therapeutics|October 20, 2021
Review article: drug-induced small bowel injuryShadi Hamdeh, Dejan Micic, Stephen Hanauer
Expert Review of Clinical Immunology|May 25, 2023
The evolving role of JAK inhibitors in the treatment of inflammatory bowel diseaseNancy Gupta, Sam Papasotiriou, Stephen Hanauer
Pageof 7